Buscar
Incyte Corp
INCYAñadir a la lista de seguimiento
119.470USD
-3.520-2.86%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
23.89BCap. mercado
16.37P/E TTM
Más Datos de Incyte Corp Compañía
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Información de Incyte Corp
Símbolo de cotizaciónINCY
Nombre de la empresaIncyte Corp
Fecha de salida a bolsaDec 06, 1993
Director ejecutivoMeury (Bill)
Número de empleados2617
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 06
Dirección1801 Augustine Cut-Off
CiudadWILMINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19803
Teléfono13024986700
Sitio Webhttps://www.incyte.com/
Símbolo de cotizaciónINCY
Fecha de salida a bolsaDec 06, 1993
Director ejecutivoMeury (Bill)
Ejecutivos de Incyte Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.06M
-34.96%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
358.08K
+22.15%
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
143.78K
+1.32%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
142.57K
+1.15%
Dr. Pablo J. Cagnoni
Dr. Pablo J. Cagnoni
President - Research and Development
President - Research and Development
81.09K
-11.74%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
76.94K
+2.13%
Mr. Thomas R. Tray
Mr. Thomas R. Tray
Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer
Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer
69.46K
+0.82%
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
60.95K
+2.69%
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Independent Director
Independent Director
47.17K
+19.54%
Mr. Lee Heeson
Mr. Lee Heeson
Executive Vice President - Incyte, International
Executive Vice President - Incyte, International
38.04K
-0.29%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.06M
-34.96%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
358.08K
+22.15%
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
143.78K
+1.32%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
142.57K
+1.15%
Dr. Pablo J. Cagnoni
Dr. Pablo J. Cagnoni
President - Research and Development
President - Research and Development
81.09K
-11.74%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
76.94K
+2.13%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Incyte Corp?
Los cinco principales accionistas de Incyte Corp son: Mr. Herve Hoppenot
¿Cuántas instituciones poseen acciones de Incyte Corp (INCY)?
A fecha de 2026Q1, 1617 instituciones poseen acciones de Incyte Corp, con un valor de mercado combinado de aproximadamente 209.33M, lo que representa el 104.84% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3757856.00.
¿Cuál es la mayor fuente de ganancias de Incyte Corp?
El 2026Q1, el segmento empresarial JAKAFI revenues generó la ganancia más alta para Incyte Corp, ascendiendo a 3.09B y representando el 60.15% de la ganancia total.